Skip to content

Site logo

Main menu
  • Home
  • Company
    • Company Overview
    • Stories
    • History
    • Our People
    • Responsibility
    • Culture & Values
    • Diversity & inclusion
  • Research
    • Research Overview
    • Discovery Centre
    • Clinical Research
    • Pipeline
  • Products
    • Products A-Z
    • Pharmaceutical Products & Vaccines Supply
  • Partnerships
    • Partnerships Overview
    • Collaborative Working
    • Third Party Organisations
    • Patient Engagement
    • Grants & Donations
    • Defend Your Tomorrow
  • Media
    • Newsroom
  • Careers
    • Careers in the UK
    • Future Talent
    • Search Jobs
Contact us

What can we help you find?

Search for:

Therapeutic Area: Infectious Disease

NOXAFIL® 100mg Gastro-resistant Tablets [posaconazole]

Therapeutic Areas

Infectious Disease

Product Information Links

SmPC

Patient Information Leaflet

NOXAFIL® Oral Suspension [posaconazole]

Therapeutic Areas

Infectious Disease

Product Information Links

SmPC

Patient Information Leaflet

LYFNUA®▼ 45mg film-coated tablets [gefapixant citrate]

Therapeutic Areas

Infectious Disease

Product Information Links

SmPC

Patient Information Leaflet

LAGEVRIO®▼ 200mg Hard Capsules [molnupiravir]

Therapeutic Areas

Infectious Disease

Product Information Links

SmPC

Patient Information Leaflet

ISENTRESS® 100mg Granules for Oral Suspension [raltegravir potassium]

Therapeutic Areas

Infectious Disease

Product Information Links

SmPC

Patient Information Leaflet

ISENTRESS® 100mg Chewable Tablets [raltegravir potassium]

Therapeutic Areas

Infectious Disease

Product Information Links

SmPC

Patient Information Leaflet

ISENTRESS® 25mg Chewable Tablets [raltegravir potassium]

Therapeutic Areas

Infectious Disease

Product Information Links

SmPC

Patient Information Leaflet

ISENTRESS® 600mg Tablets [raltegravir potassium]

Therapeutic Areas

Infectious Disease

Product Information Links

SmPC

Patient Information Leaflet

ISENTRESS® 400mg Tablets [raltegravir potassium]

Therapeutic Areas

Infectious Disease

Product Information Links

SmPC

Patient Information Leaflet

INVANZ® Powder for Concentrate for Solution for Infusion [ertapenem sodium]

Therapeutic Areas

Infectious Disease

Product Information Links

SmPC

Patient Information Leaflet

Posts navigation

Older posts
Newer posts

Connect with us:

Twitter icon Facebook icon Linkedin icon Instagram icon YouTube icon
  • UK Newsroom
  • Contact Us
  • Corporate Responsibility
  • MSD for Mothers
  • Social Media Guidelines
  • UK Tax Strategy
  • Copyright
  • MSD Modern Slavery Statement
  • Patient Engagement
  • UK Animal Health
  • US Corporate Site
  • MSD Manuals
  • Investors
  • Licensing
  • Privacy Policy
  • Cookie Policy
  • Copyright
  • Terms of use
  • General Public Privacy Notice
  • Accessibility
Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept